LB059 - EFFECTIVENESS AND TOLERABILITY OF A NOVEL ORAL NUTRITIONAL SUPPLEMENT IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE (IBD): A PRELIMINARY REPORT FROM A REFERRAL CENTER.
LB059
EFFECTIVENESS AND TOLERABILITY OF A NOVEL ORAL NUTRITIONAL SUPPLEMENT IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE (IBD): A PRELIMINARY REPORT FROM A REFERRAL CENTER.
R. Majer1,*, S. Gammino2, S. C. Ciminnisi2, O. Giambò2, C. Amari2, A. Lo Leggio2, G. Pennisi2, L. Vitiello1, M. Cappello2
1Lionhealth S.r.l SB, Milano, 2ProMISE Department, Gastroenterology and Hepatology Section, University of Palermo, Palermo, Italy
Rationale: Malnutrition and sarcopenia are common in IBD and negatively influence response to biologics;oral nutritional supplements (ONS) is often poorly tolerated. This study evaluates the efficacy and tolerability of a novel ONS, characterized by low osmolarity, high protein content, a patent blend of polyphenol-rich extracts in patients at risk of or with malnutrition.
Methods: We enrolled 14 IBD patients with moderate-to-severe disease based on clinical and biochemical indices, all receiving biologics. Nutritional assessment was performed at baseline and after 3 months of novel ONS using anthropometry (BMI,MAMC,hand grip strength), BIA, and screening tools (MUST,GLIM,MNA).
Results: At baseline,57.1% of patients had severe malnutrition (GLIM stage 2),64.3% per MUST (≥ 2) and MNA, a median BMI 19±1.3 kg/m², handgrip strength 27±9.1 kg, phase angle 5.5±1, skeletal muscle index (SMI) 8.6 ± 1 kg/m², and mid-arm muscle circumference (MAMC) 23.45±2.7 cm. After 3 months of treatment, nutritional risk scores improved significantly; no patients were classified as malnourished by MNA or MUST≥ 2, and only 8.3% met GLIM stage 2. At the end of the follow-up, body weight increased by 6.5%, with a median BMI 20.4±1.7 (+7.4%,p=0.030), MAMC 25.62±1.3 cm (+9.3%,p=0.015), hand grip strength 32.95±10.67, phase angle 5.7±0.86, SMI 9.17±1.32 kg/m². Biochemical and clinical activity indices also improved. ONS was well tolerated in 85.7% of patients.Two pts drop out:one for worsening of diarrhoea in short bowel syndrome and other for poor adherence.
Conclusion: The novel ONS was effective and safe in improving nutritional status in active IBD pts, supporting the role of a tailored nutritional combined with pharmacological therapy to optimize outcomes.
References: Balestrieri, M et al. Nutrients. 2020 Jan 31;12(2):372. Bezzio, D. et al. Nutrients 2024 Nov 21;16(23):3983.
Disclosure of Interest: R. Majer Shareholder of: 0,18% share, S. Gammino: None declared, S. C. Ciminnisi: None declared, O. Giambò: None declared, C. Amari: None declared, A. Lo Leggio: None declared, G. Pennisi: None declared, L. Vitiello Other: na, M. Cappello: None declared